MAGGIC risk score and drug-related adverse events of sacubitril/valsartan: Insights from the REVIEW-HF registry
The MAGGIC risk score was associated with DAEs risk following sacubitril/valsartan initiation in patients with HF. The impact of DAEs on outcomes varied across risk tertiles, suggesting potential utility for risk stratification and monitoring approaches in HF management.
Authors
- Shingo Matsumoto (ORCID: https://orcid.org/0000-0003-2698-0839)
- Yoshihiro Fukumoto (ORCID: https://orcid.org/0000-0002-8947-109X)
- Daiki Akagaki
- Wataru Fujimoto (ORCID: https://orcid.org/0000-0001-8832-7435)
- Tatsuhiro Shibata (ORCID: https://orcid.org/0000-0002-0477-210X)
- Koshiro Kanaoka (ORCID: https://orcid.org/0000-0001-7900-7835)
- Takahito Nasu (ORCID: https://orcid.org/0000-0001-5631-6870)
- Takeshi Ijichi (ORCID: https://orcid.org/0000-0002-1950-7616)
- Keisuke Kida
- Nobuyuki Kagiyama (ORCID: https://orcid.org/0000-0002-2305-0049)
- Shunsuke Ishii (ORCID: https://orcid.org/0000-0003-2111-6304)
- Kodai Shibao
- Atsushi Kikuchi
Institutions
- Kurume University (JP)
- Toho University (JP)
- Tokai University (JP)
- Johns Hopkins University (US)
- St. Marianna University School of Medicine (JP)
- Iwate Medical University (JP)
- Osaka Prefectural Medical Center (JP)
- British Heart Foundation (GB)
- Juntendo University (JP)
- Hyogo Prefectural Awaji Medical Center (JP)
- Osaka City General Hospital (JP)
- National Cerebral and Cardiovascular Center (JP)
- Kitasato University (JP)
- Nara Medical University (JP)
- University of Glasgow (GB)
Publication Details
- Journal
- IJC Heart & Vasculature
- Published
- 2025-05-10
- DOI
- https://doi.org/10.1016/j.ijcha.2025.101702
- Citations
- 1
- Primary Topic
- Heart Failure Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.39